▲ +11.16% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Collegium Pharmaceutical in the last 3 months. The average price target is $25.00, with a high forecast of $34.00 and a low forecast of $8.00. The average price target represents a 11.16% upside from the last price of $22.49.
The current consensus among 4 contributing investment analysts is to hold stock in Collegium Pharmaceutical. This rating changed within the last month from a Buy consensus rating.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, and injecting. The company also offers Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. In addition, it offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.